Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrilizumab + Bevacizumab + Capecitabine in HNSCC
NCT05965154Phase 2Unknown
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05965154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965154.